Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
The present invention includes methods for treating a proliferative disorder comprising administering a therapeutically effective amount of crenolanib or a salt thereof in combination with pharmaceutical agent targeting apoptosis pathway proteins wherein the crenolanib and other agent are provided at least one of sequentially or concomitantly in a subject for use in the treatment of the proliferative disease, wherein the subject is a human subject.
1. A method for treating a proliferative disorder comprising administering to a subject a therapeutically effective amount of crenolanib or pharmaceutically acceptable salt thereof in combination with a hypomethylating agent or DNA methyltransferase inhibitor.
2. The method of claim 1 , wherein the hypomethylating agent is azacitidine or decitabine.
3. The method of claim 1 , wherein the proliferative disorder is characterized by a constitutively active mutated FLT3, or wherein the mutated FLT3 is selected from at least one of FLT3-ITD, FLT3-TKD, or FLT3-variants.
4. The method of claim 1 , wherein the proliferative disorder is selected from at least one of a leukemia, myeloma, myeloproliferative disease, myelodysplastic syndrome, idiopathic hypereosinophilic syndrome, bladder cancer, breast cancer, cervical cancer, central nervous system cancer, colon cancer, esophageal cancer, head and neck cancer, liver cancer, lung cancer, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, small cell lung cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, and hematologic malignancy.
5. The method of claim 1 , wherein the subject has a newly diagnosed proliferative disorder.
6. The method of claim 1 , wherein the crenolanib or pharmaceutically acceptable salt thereof and the hypomethylating agent or DNA methyltransferase inhibitor are administered one of sequentially or concomitantly with the hypomethylating agent or DNA methyltransferase inhibitor.
7. The method of claim 1 , wherein the therapeutically effective amount of crenolanib or the pharmaceutically acceptable salt thereof is from about 50 to 500 mg per day, 100 to 450 mg per day, 200 to 400 mg per day, 300 to 500 mg per day, 350 to 500 mg per day, or 400 to 500 mg per day.
8. The method of claim 1 , wherein the crenolanib or the pharmaceutically acceptable salt thereof is crenolanib besylate, crenolanib phosphate, crenolanib lactate, crenolanib hydrochloride, crenolanib citrate, crenolanib acetate, crenolanib toluenesulphonate, and crenolanib succinate.
9. The method of claim 1 , wherein the crenolanib or pharmaceutically acceptable salt thereof and the hypomethylating agent or DNA methyltransferase inhibitor are administered at least one of continuously, intermittently, systemically, or locally for as long as the subject is in need of treatment for the proliferative disorder.
10. The method of claim 1 , wherein the crenolanib or pharmaceutically acceptable salt thereof and the hypomethylating agent or DNA methyltransferase inhibitor are administered orally, intravenously, or intraperitoneally.
11. The method of claim 1 , wherein the crenolanib or pharmaceutically acceptable salt thereof and the hypomethylating agent or DNA methyltransferase inhibitor are administered up to three times a day.
12. The method of claim 1 , wherein the subject has progressed on at least one prior line of therapy.
13. The method of claim 1 , wherein the subject is in need of therapy to maintain remission.